General form of registration statement for all companies including face-amount certificate companies

INTANGIBLE ASSETS

v3.23.3
INTANGIBLE ASSETS
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

 

 

    Estimated life   June 30,
2023		     December 31,
2022		  
Website   3 years   $ 10,799     $ 10,799  
Accumulated amortization         (10,499 )     (8,699 )
Intangible assets, net       $ 300     $ 2,100  

 

As of June 30, 2023, estimated future amortization expenses related to intangible assets were as follows:

 

 

      Intangible Assets  
2023   $ 300  
Intangible assets, net   $ 300  

 

The Company had amortization expense of $900 and $1,800, and $900 and $1,800 for the three and six months ended June 30, 2023 and 2022, respectively.

 

 

NOTE 5 – INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

    Estimated life   December 31, 2022     December 31, 2021  
Website   3 years   $ 10,799     $ 10,799  
Accumulated amortization         (8,699 )     (5,099 )
Intangible assets, net       $ 2,100     $ 5,700  

 

As of December 31, 2022, estimated future amortization expenses related to intangible assets were as follows:

    Intangible Assets  
2023   $ 2,100  
 Intangible assets, net   $ 2,100  

 

The Company had amortization expense of $3,600 and $16,205 for the years ended December 31, 2022 and 2021, respectively.

 

On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s CTO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood.